GeoVax Labs Inc (GOVX)
GeoVax Labs Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. Based in the United States and headquartered in Smyrna, Georgia, the company works on preventive and therapeutic candidates targeting conditions including COVID-19, HIV, Zika, malaria, and hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa, as well as chronic hepatitis B and certain solid tumors. Its pipeline includes GEO-CM04S1, which is in Phase 2 clinical testing for COVID-19; Gedeptin, a patented program being evaluated in Phase 1/2 for advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine candidate. GeoVax also has preclinical programs such as GEO-MVA-MUC1, GEO-ZM02, GEO-EMO1-Z, GEO-EMO1-S, GEO-MM01, and GEO-MVA. The company has collaboration agreements with NIAID, the U.S. Department of Defense, and the Burnet Institute.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GOVX
|
$0.43
|
17.2% Upside
|
Fair
|
$10 2,652.5% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 5, 2026
|
1.9x
|
3.304 M
|
483.522 K
|
9.0%
|
93.9%
|
-61.9
|
89.9%
|
